Mode
Text Size
Log in / Sign up
Phase 2 N=97 Randomized Double-blind Treatment

The Effects of Physical Activity and Low-Dose Ibuprofen on Cognitive Function in Cancer Patients

Cancer-related Cognitive Difficulties

Enrolled (actual)
97
Serious AEs
4.1%
Results posted
Mar 2021
Primary outcome: Primary: Memory Performance as Assessed by Computerized Cognitive Assessment - Mean Values by Arm — 75.2; 82.7; 83.6; 74.3 % correct — p=0.9168

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
Ibuprofen (Drug); Home-Based Exercise (Behavioral); Placebo (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
University of Rochester
Primary completion
Dec 2019

Outcome Measures

OutcomeResultp-value
PRIMARY
Memory Performance as Assessed by Computerized Cognitive Assessment - Mean Values by Arm
75.2; 82.7; 83.6; 74.3; 89.4; 90.0 0.9168
SECONDARY
Cognitive Functioning Score as Assessed by FACT-COG Questionnaire - Perceived Cognitive Impairment (PCI) - Mean Values by Arm
74.7; 72.7; 85.9; 76.2; 80.5; 76.5 0.6536

Summary

This research seeks to determine if a combination of low-dose ibuprofen along with a structured home-based walking and progressive resistance exercise program, EXCAP, will be effective in reducing cognitive difficulties among cancer patients receiving chemotherapy.

Eligibility Criteria

Inclusion Criteria

  • Must report cognitive difficulties of 3 or higher on a 0-10 scale
  • Must provide informed consent
  • Be able to read English
  • Have a primary diagnosis of cancer
  • Be able to swallow medication
  • Women of child-bearing potential must not be pregnant or become pregnant during the 6 week study
  • Agree not to take NSAIDs during the 6 week intervention period
  • Be scheduled to receive at least 2 additional cycles of oral or IV chemotherapy over the 42-day study period.
  • Must have the approval of their treating physician to begin the exercise program and receive the ibuprofen
  • Must be over 18 years of age

Exclusion Criteria

  • Currently taking a consistent dosage of a NSAID at least 3 days a week for the last 3 months that is over 400mg daily
  • Have an allergy to ibuprofen
  • Be identified as in active or maintenance stage of exercise behavior as assessed by the single-item exercise stages of change short form
  • have physical limitations that contraindicate participation in sub-maximal physiological fitness testing or a low to moderate home-based walking and progressive resistance program
  • have a history of peptic ulcer disease within the last 12 months
  • Diagnosed with a neurodegenerative disease
  • Had a myocardial infraction within the past 6 months
  • Patients with a neutropenic episode during the first cycle of chemotherapy or at high risk for a neutropenic episode during future chemotherapy cycles at the treating physicians discretion
  • Have confirmed metastatic disease to the central nervous system
  • Have been hospitalized for a major psychiatric illness within the last 5 years
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01238120). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search